Compare · MTD vs PACB
MTD vs PACB
Side-by-side comparison of Mettler-Toledo International Inc. (MTD) and Pacific Biosciences of California Inc. (PACB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MTD and PACB operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- MTD is the larger of the two at $28.03B, about 70.4x PACB ($397.9M).
- Over the past year, MTD is up 8.4% and PACB is down 3.4% - MTD leads by 11.8 points.
- Both names hit the wire about 7 times in the past 4 weeks.
- PACB has more recent analyst coverage (24 ratings vs 23 for MTD).
- Company
- Mettler-Toledo International Inc.
- Pacific Biosciences of California Inc.
- Price
- $1398.74+0.30%
- $1.28-6.91%
- Market cap
- $28.03B
- $397.9M
- 1M return
- +5.29%
- -5.19%
- 1Y return
- +8.44%
- -3.40%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1997
- 2010
- News (4w)
- 7
- 7
- Recent ratings
- 23
- 24
Mettler-Toledo International Inc.
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. It markets its products through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.
Pacific Biosciences of California Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Latest MTD
- Director Salice Thomas P exercised 417 shares at a strike of $397.95 and sold $600,651 worth of shares (417 units at $1,440.41) (SEC Form 4)
- Director Salice Thomas P exercised 415 shares at a strike of $397.95 and sold $599,517 worth of shares (415 units at $1,444.62) (SEC Form 4)
- Head of Process Analytics Keller Gerry exercised 240 shares at a strike of $720.81 and sold $342,514 worth of shares (240 units at $1,427.14) (SEC Form 4)
- Chief Financial Officer Vadala Shawn exercised 2,240 shares at a strike of $595.31 and sold $3,207,680 worth of shares (2,240 units at $1,432.00) (SEC Form 4)
- SEC Form 3 filed by new insider Shuman-Fabbri Natalia
- Mettler-Toledo International Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Natalia Shuman Joins Mettler Toledo Board of Directors
- SEC Form 10-Q filed by Mettler-Toledo International Inc.
- Mettler-Toledo International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Mettler-Toledo International Inc. Reports Second Quarter 2026 Results
Latest PACB
- Officer Van Oene Mark sold $30,409 worth of shares (26,911 units at $1.13), decreasing direct ownership by 0.98% to 2,705,853 units (SEC Form 4) to satisfy withholding obligation
- Officer Van Oene Mark was granted 489,130 shares, increasing direct ownership by 22% to 2,732,764 units (SEC Form 4)
- SEC Form 10-Q filed by Pacific Biosciences of California Inc.
- Pacific Biosciences of California Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- PacBio Appoints Mark Van Oene as President and Chief Executive Officer
- PacBio Announces Second Quarter 2026 Financial Results
- PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system
- PacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference
- PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026
- Pacific Biosciences of California Inc. filed SEC Form 8-K: Leadership Update